Three Big Biotech Buybacks That Investors Should Love
Large-cap biotech stocks have been on a tear over the past few years, crushing the overall market return. Thanks to strong execution and a slew of new drug launches, these companies have found themselves flush with extra cash and have announced multibillion-dollar buyback programs. But are these share repurchase programs big enough to move the needle?
Hey, check out all the research scientist jobs. Post your resume today!
Hey, check out all the research scientist jobs. Post your resume today!